Adam C. Welch, PharmD, MBA, FAPhA: So if these monoclonal antibodies are relatively short as far as the duration of protection that they provide and we’re not quite sure when the RSV ...

A new study shows that previous treatments with monoclonal antibodies may impact your future immune defenses against Covid-19.

Pharma company Invivyd, Inc. just announced it is working with the US Food and Drug Administration (FDA) on a pathway to ...

As cold and flu season ramps up, the most vulnerable among us need extra protection. Infants are among the most susceptible to respiratory complications from respiratory syncytial virus, or RSV. While ...

The updated NCCN Guidelines now include the recommendation for monoclonal antibodies for pre-exposure prophylaxis against COVID-19, highlighting the significance of Invivyd's products in cancer ...

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in ...

SpikImm is focused on the accelerated development of long-acting monoclonal antibodies to protect immunocompromised patients from several viral infections, including SARS-CoV-2 and BKV.